Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 12, 2010, Pages 1751-1755

  Van Biervliet, Stephanie ^a   Van Biervliet, Jean Pierre ^a   Robberecht, Eddy ^a   Christophe, Armand ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

cystic fibrosis; fatty acid; liver disease

Indexed keywords

ADRENIC ACID; ALPHA TOCOPHEROL; DOCOSAHEXAENOIC ACID; FATTY ACID; PHOSPHOLIPID;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED LIVER DISEASE; DISEASE SEVERITY; FEMALE; FOOD INTAKE; GENOTYPE; HUMAN; LIPID COMPOSITION; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; SEA FOOD; VITAMIN BLOOD LEVEL;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CYSTIC FIBROSIS; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS; FEMALE; GENOTYPE; HUMANS; LIVER DISEASES; MALE; PHOSPHOLIPIDS; VITAMIN E; YOUNG ADULT;

EID: 78951484266     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.336     Document Type: Article

References (43)

1. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73: 1251-4.
2. Roulet M, Frascardo P, Pilet M. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur J Pediatr 1997;156:952-6.
3. Farrell PM, Mischler EH, Engle MJ, Brown J, Lau SM. Fatty acid abnormalities in cystic fibrosis. Pediatr Res 1985;19: 104-9.
4. Robinson PG. Essential fatty acids in cystic fibrosis. Lancet 1975;8:919.
5. Rogiers V, Dab I, Crokaert R, Vis HL. Long chain non-esterified fatty acid pattern in plasma of cystic fibrosis patients and their parents. Pediatr Res 1980;14:1088-91.
6. Dodge JA, Salter DG, Yassa JG. Essential fatty acid deficiency due to artificial diet in cystic fibrosis. Br Med J 1975;11:192-3.
7. Gibson RA, Teubner JK, Haines K, Cooper DM, Davidson GP. Relationships between pulmonary function and plasma fatty acid levels in cystic fibrosis patients. J Pediatr Gastroenterol Nutr 1986;5:408-15.
8. Christophe A, Robberecht E. Current knowledge on fatty acids in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 1996;55:129-38.
9. Freedman SD, Blanco PG, Zaman MM, SHEA JC, Ollero M, Hopper IK, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004;350:560-9.
10. Van Biervliet S, Van Biervliet JP, Robberecht E, Christophe A. Docosahexanoic acid trials in cystic fibrosis: a review of the rationale behind the clinical trials. J Cyst Fibr 2005;4:27-34.
11. Kuratko CN, Salem N Jr. Biomarkers of DHA status. Prostaglandins Leukot Essent Fatty Acids 2009;81:111-8.
12. Kalivianakis M, Minich DM, Bijleveld CM, Van Aaldreren WM, Stellaard F, Laseur M, et al. Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy due to impaired intestinal uptake of long-chain fatty acids. Am J Clin Nutr 1999;69:127-34.
13. Rogiers V, Dab I, Michotte Y, Vercruysse A, Crockaert R, Vis HL. Abnormal fatty acid turnover in the phospholipids of the red blood cell membranes of cystic fibrosis patients (in vitro study). Pediatr Res 1984;18:704-9.
14. Carlstedt-Duke J, Bronnegard M, Strandvik B. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc Natl Acad Sci USA 1986;83: 9202-6.
15. Levistre R, Lemnaouar M, Rybkine T, Bereziat G, Masliah J. Increase of bradykinin stimulated arachidonic acid release in a delta-F508 cystic fibrosis epithelial cell line. Biochim Biophys Acta 1993;1181:233-9.
16. Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in CFTR-/-mice. Proc Natl Acad Sci USA 1999;96:13995-40000.
17. Dombrowsky H, Clark GT, Rau GA, Bernhard W, Postle AD. Molecular species compositions of lung and pancreas phospholipids in the CFTR(tm1HGU/tm1HGU) cystic fibrosis mouse. Pediatr Res 2003;53:447-54.
18. Werner A, Bongers ME, Bijvelds MJ, de Jonghe HR, Verkade HJ. No indications for altered essential fatty acid metabolism in two murine models for cystic fibrosis. J Lipid Res 2004;45: 2277-86.
19. Strandvik B, Gronowitz E, Enlund F, Martinsson T, Wahlstörm J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J Pediatr 2001;139:650-5.
20. Van Biervliet S, Van Billemont G, Van Biervliet JP, Declercq D, Robberecht E, Christophe A. Relation between fatty acid composition and clinical status or genotype in cystic fibrosis patients. Ann Nutr Metab 2007;51:541-9.
21. Socha P, Koletzko B, Swiatkowska E, Pawlowska J, Stolarczyk A, Socha J. Essential fatty acid metabolism in infants with cholestasis. Acta Paed 2001;87:278-83.
22. Robberecht E, Koletzko B, Christophe A. Several mechanisms contribute to the abnormal fatty acid composition of serum phospholipids and cholesterol esters in cholestatic children with extrahepatic biliary atresia. Prostaglandins Leukot Essent Fatty Acids 1997;56:199-204.
23. Clemmesen JO, Hoy CE, Jeppesen PB, Ott P. Plasma phospholipid fatty acid pattern in severe liver disease. J Hepatol 2000; 32:481-7.
24. Watanabe A, Saito S, Tsuchida T, Higuchi K, Okita M. Low plasma levels of docosahexaenoic acid in patients with liver cirrhosis and its correction with polyunsaturated fatty acidenriched soft oil capsule. Nutrition 1999;15:284-8.
25. Munnik P, Zanen P, Lammers JW. A comparison of lung function equipement with emphasis on interchangeability and methods. Physiol Meas 2006;27:445-55.
26. Walkowiak J, Nousia-Arvanitakis S, Cade A, Kashirskaya N, Piotrowski R, Strzykala K, et al. Fecal elastase-1 cut-off levels in the assessment of exocrine pancreatic function in cystic fibrosis. J Cyst Fibros 2000;1:260-4.
27. Williams SG, Evanson JE, Barrett N, Hodson ME, Boultbee JE, Westaby D. An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J Hepatol 1995;22:513-21.
28. Robberecht E, Van Biervliet S, Vanrentergem K, Kerremans I. Outcome of total splenectomy with portosystemic shunt for massive splenomegaly and variceal bleeding in cystic fibrosis. J Pediatr Surg 2006;41:1561-5.
29. Folch-Pi J, Lees M, Stanly GS. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
30. Christophe A, Matthijs F. New method for the determination of the fatty acid pattern of serum lipid classes. Clin Chim Acta 1967;16:39-43.
31. Muskiet FA, Van Doormaal JJ, Mastini IA, Wolters BG, Van der Slik W. Capillary gas chromatography profiling of total long-chain fatty acids and cholesterol in biological materials. J Chromatogr 1983;278:231-44.
32. Driskoll WJ, Neese JW, Bryant CC, Bashor MM. Measurement of vitamin A and E in human serum by high performance liquid chromatography. J Chromatogr Biomed Sc Appl 1982;231: 439-44.
33. Sioen IA, Pynaert I, Matthys C, De Backer G, Van Camp J, De Henauw S. Dietary intakes and food sources of fatty acids for Belgian women, focused on n-6 and n-3 polyunsaturated fatty acids. Lipids 2006;41:415-22.
34. Borot F, Vieu DL, Faure G, Fritsch J, Colas J, Moriceau S, et al. Eicosanoid release is increased by membrane destabilization and CFTR inhibition in Calu-3 cells. PLoS One 2009 22;4: e7116.
35. Diwakar V, Pearson L, Beath S. Liver disease in children with cystic fibrosis. Paed Resp Rev 2001;2:340-9.
36. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. J Ped Gastroenterol Nutr 1999;S1:1-13.
37. Lepage G, Paradis K, Lacaille F, Senechal L, Ronco N, Champagne J, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Pediatr 1997;130:52-8.
38. Cosgrove JP, Church DF, Pryor WA. The kinetics of the autooxidation of PUFA. Lipids 1987;22:299-304.
39. Harper TB, Chase HP, Henson J, Henson PM. Essential fatty acid deficiency in the rabbit as a model of nutritional impairment in cystic fibrosis: in vitro and in vivo effects on lung defence mechanisms. Am Rev Respir Dis 1982;126:540-7.
40. Lindbald A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999;5:1151-8.
41. Strandvik B, Hultcrantz R. Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. Liver 1994;14:32-6.
42. Brigman C, Feranchak A. Liver involvement in cystic fibrosis. Curr Treat Options Gastroenterol 2006;9:484-96.
43. Beharry S, Ackerley C, Corey M, Kent G, Heng YM, Christensen H, et al. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. AJP Gastrointest liver Physiol 2007;292:G839-48.